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Abstract
Embryonal tumor with abundant neuropil and true rosettes (ETANTR) is a recently
described embryonal neoplasm of the central nervous system, consisting of a well-
circumscribed embryonal tumor of infancy with mixed features of ependymoblastoma
(multilayer ependymoblastic rosettes and pseudorosettes) and neuroblastoma (neuro-
blastic rosettes) in the presence of neuropil-like islands. We present the case of a young
child with a very aggressive tumor that rapidly recurred after gross total resection, chemo-
therapy and radiation. Prominent vascular sclerosis and circumscribed tumor led to the
diagnosis of malignant astroblastoma; however, rapid recurrence and progression of
this large tumor after gross total resection prompted review of the original pathology.
ETANTR is histologically distinct with focal glial fibrillary acid protein (GFAP) and
synaptophysin expression in the presence of neuronal and ependymoblastic rosettes with
focal neuropil islands. These architectural features, combined with unique chromosome
19q13.42 amplification, confirmed the diagnosis. In this report, we describe tumor stem
cell (TSC) marker CD133, CD15 and nestin alterations in ETANTR before and after
chemotherapy. We found that TSC marker CD133 was richly expressed after chemo-
therapy in recurrent ETANTR, while CD15 is depleted compared with that expressed in
the original tumor, suggesting that CD133+ cells likely survived initial treatment, further
contributing to formation of the recurrent tumor.
INTRODUCTION
Embryonal tumors are malignant neoplasms that predominantly
affect children. According to the 2007 World Health Organization
(WHO) classification of central nervous system (CNS) tumors,
there are three types of embryonal tumors: medulloblastoma,
atypical teratoid/rhabdoid tumor (AT/RT) and primitive neuro-
ectodermal tumor (PNET) (23, 24). PNETs are further subdivided
into neuroblastoma, ganglioneuroblastoma, medulloepithelioma,
ependymoblastoma and PNET-not otherwise specified (NOS).
Embryonal tumor with abundant neuropil and true rosettes
(ETANTR) is considered a variant within the PNET-NOS category
of the WHO classification. Because of its unique clinical and
histological features, it has been suggested that this tumor may
eventually be considered a separate entity (1).
ETANTR was first described in 2000 by Eberhart et al (8). They
reported on nine children with tumors that had hybrid features
of both cerebral neuroblastoma and ependymoblastoma along
with unique histological, immunohistochemical and ultrastructural
characteristics. The composite features of ETANTR as initially
observed by Eberhart et al (8) included fine and abundant fibrillary
neuropil, undifferentiated neuroepithelial cells arranged in clusters
and several types of rosettes, such as Homer-Wright, Flexner–
Wintersteiner and ependymoblastic like. Recently a specific ampli-
fication of 19q13.42 region containing a cluster of microRNA
(miR) coding genes was found in embryonal tumors with
multilayered rosettes, which can be helpful in narrowing the diag-
nosis of these primitive tumors (15, 21, 30). To date, 30 cases of
ETANTR have been reported in the literature (8, 16, 17, 26, 35).
Age at diagnosis ranged from 6 months to 4 years. ETANTR is
associated with high potential for malignancy and poor prognosis
(19). Mean survival is approximately 16 months, although one
long-term survivor after 7 years of follow-up has been reported
(7, 16, 26, 35).
The tumor stem cell (TSC) theory suggests that the tumorigenic
potential of CNS tumors is limited to a subpopulation of cells
with stem-like properties (CD133, CD15) (2, 33). It has been
further suggested that these subpopulations confer chemothe-
rapy and radiation resistance by their slow growth and ability to
remain dormant, evading conventional therapeutic strategies (31).
ETANTR remains poorly characterized clinically as well as
pathologically. The characterization of tumor stem-like cells in
ETANTR will improve our understanding of this disease, leading
to a better understanding of tumor biology and treatment design. In
this study, we investigate the presence of stem-like cell tumor
markers CD133, CD15 and nestin from initial diagnosis, tumor
recurrence and within different regions of a single ETANTR
tumor.
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CLINICAL HISTORY
A 3-year-old girl presented with a 4-day history of worsening
headache, nausea, vomiting and ataxia. After presentation, she
became somnolent and her Glasgow Coma Score (GCS) dropped
from 15 on presentation to 10. She was intubated and transferred
to our hospital for further management.
T1-weighted head magnetic resonance imaging (MRI;
Figure 1A) showed a heterogeneous mass in the left frontoparietal
region measuring 6.5 × 5.5 cm with areas of calcification and
hydrocephalus. The patient underwent a left parietal occipital cra-
niotomy for tumor resection. Gross total resection was achieved
(Figure 1B). Tumor pathology was initially interpreted as malig-
nant astroblastoma. The patient was treated under Children’s
Cancer Group Protocol 99703 and received three cycles of
multiagent chemotherapy, including vincristine, etoposide and
Cytoxan. This was followed by three cycles of non-ablative stem
cell chemotherapy with carboplatin and thiotepa. Follow-up MRI
of the brain 6 months after initial craniotomy revealed no evidence
of recurrence. Routine 8-month surveillance MRI demonstrated
an enhancing mass in the left parietal occipital surgical resection
cavity measuring 3.8 cm in maximal diameter (Figure 1C). A
second tumor resection was performed, after which postoperative
MRI scan demonstrated gross total resection. Following the
second resection, the tumor was reclassified as an ETANTR rather
than malignant astroblastoma.
The patient was treated with craniospinal proton beam radiation.
Four months following the second surgery, she became progres-
sively somnolent with worsening headaches and vomiting. MRI
revealed infiltrative tumor with diffuse leptomeningeal spread to
intraventricular, supratentorial and infratentorial locations, along
with coating of multiple cranial nerves and nodular disease in the
entire spine (Figure 1D). Treatment with temozolomide, irinotecan
and Avastin was initiated. The patient died of disease progression
13 months after initial diagnosis and 5 months following initial
recurrence.
METHODS
DNA, RNA and total protein were extracted from tumor samples at
the time of initial resection and recurrence. Regional tumor het-
erogeneity was examined in the recurrent tumor by taking speci-
mens from the tumor core and periventricular regions closest to the
subventricular zone as evident at the time of surgery via the use of
stereotactic navigation. Tissue protein, total RNA and DNA were
isolated using previously established protocols (10).
Immunohistochemistry
Immunohistochemical analysis was performed on paraffin-
embedded and frozen sections according to established protocols
(10). Primary antibodies included GFAP (polyclonal, 1:3200;
DAKO Corp., Carpinteria, CA, USA), synaptophysin (prediluted,
clone SP11; Ventana Medical Systems, Inc., Oro Valley, AZ,
USA), INI-1 (prediluted clone MRQ-17; Cell Marque Corp.,
Rocklin, CA, USA) and Ki-67 (prediluted, clone 30-9; Ventana
Medical Systems), nestin (AB5922 rabbit polyclonal, 1:1000;
Millipore, Billerica, MA, USA), CD133 [3663 rabbit monoclonal
immunoglobulin G (IgG), 1:100; Cell Signaling, Boston, MA,
USA)] and CD15 (4744 mouse monoclonal IgM, 1:100; Cell
Signaling). The percentage of cells that displayed positive
immunoreactivity for CD15 and CD133 were calculated by
analyzing five images taken in 10 random sections at 40× magni-
fication based on a standard grid system. Positive control staining
was performed using cultured human glioblastoma cell line, and
negative control staining was performed using sections incubated
in primary antibody dilution buffer without the primary antibody.
Counts were performed by two masked independent investigators
(DBA and ACW). Mean cell count for positive immunoreactivity
was recorded, and a one-way analysis of variance (ANOVA) was
performed to analyze the differences between CD133+ and CD15+
populations in the tumor before chemotherapy and after chemo-
therapy in the core and periventricular regions. All statistical
analysis was performed using PASW Statistics 18 software (SPSS
Inc., Chicago, IL, USA).
Real-time reverse transcription polymerase
chain reaction (PCR)
The protocol followed for quantitative reverse transcription-PCR
(RT-PCR) for CD133, CD15 and chromosome 19q13.42 has pre-
viously been described by Fan et al (9). PCR primers used for the
Figure 1. Axial contrast-enhanced T1-weighted magnetic resonance
images (MRIs). A. Preoperative image demonstrating a 6.5 × 5.5 cm
heterogeneous mass in left parietal region. B. Postoperative MRI fol-
lowing gross total resection. C. Axial MRI 8 months postoperatively
reveals recurrent tumor within the resection cavity of the initial tumor.
D. MRI 4 months after a second craniotomy reveals progression of
disease with numerous new small lesions along brain surface and
cranial nerves, most notably in posterior fossa, periventricular region
and along the surgical cavity.
Role of CD133+ Cells in Recurrent ETANTR Hervey-Jumper et al
46 Brain Pathology 24 (2014) 45–51
© 2013 International Society of Neuropathology
analysis of chromosome 19q13.42 amplification were designed
to amplify the coding region for miR-512. PCR primers used for
the analysis of miR-512 were miR-512-QF (forward primer: 5′-
GAGCCACTGCAGGTAAAAGC-3′) and miR-512-QR (reverse
primer: 5′-CAGGCTATCCCTGAATCCAA-3′). Amplification of
miR-512 was compared with amplification of the coding region for
KIR3DL3, a natural killer cell receptor that is located on 19q13.42
and has been shown to remain unamplified in PNETs (21). The
primer sequences used for KIR3DL3 were 19q13.42 forward
(forward primer: 5′-CACCTTCTAAACTCACAACCT-3′) and
19q13.42 reverse (reverse primer: 5′-CTGTCTCTTCTGATTT
CACCA-3′). The reactions for CD15 and CD133 were normalized
to β-actin, while the reactions for miR-512 amplification were
normalized to that of three non-pooled samples of normal human
brain tissue. All samples were analyzed in triplicate and confirmed
via two separate trials.
Protein analysis
Western blot analysis was performed according to established pro-
tocols (10) to compare stem cell marker expression levels in the
pre-chemotherapy tumor sample with those in the core and
periventricular regions of the recurrent tumor following chemo-
therapy. Primary antibodies were directed against CD133 (3663,
1:1000; Cell Signaling).
RESULTS
Anatomic pathology and analysis of
19q13.42 amplification
Histology sections of the initial specimen showed a highly necrotic
tumor, composed of small round blue cells with high nuclear-
to-cytoplasmic ratio, numerous mitoses and apoptotic bodies.
Neoplastic cells arranged around sclerotic blood vessels formed
pseudorosettes. True rosette formations were also present, some
of which were multilayered. Focally the tumor had prominent
neuropil islands when highlighted by synaptophysin. The tumor
showed only focal GFAP immunoreactivity, with normal preser-
vation of INI-1 expression and markedly elevated proliferation
index (Ki-67). Trichrome highlighted prominent hyalinization of
some vessels surrounded by tumor (Figure 2). The latter finding,
in association with only focal GFAP expression in the presence of
Figure 2. Tumor histopathology [embryonal tumor with abundant
neuropil and true rosettes (ETANTR) ]. First resection (A–H):
A. Largely necrotic tumor with viable cells predominately present
around hyalinized blood vessels. B. The tumor is composed of
small round blue cells, some of them forming ependymal (*),
ependymoblastic (**) and neuronal rosettes (∧). C. Hematoxylin
and eosin (H&E) staining shows neuropil islands around the tumor.
D. Synaptophysin highlights neuropil. E. Trichrome demonstrates
prominent perivascular hyalinization. F. GFAP shows only focal
immunoreactivity of tumor cells. G. INI-1 is preserved. H. Proliferation
index (Ki-67) is highly elevated. Second resection (I–L): I. Second
resected specimen demonstrates a well-circumscribed tumor with sur-
rounding gliotic and mildly ischemic brain parenchyma. J. Small round
blue cells, similar to original resection, with pseudorosettes and true
rosette formation. K. GFAP demonstrates similar focal immunoreactivity
of tumor cells. L. In addition, some tumor cells are also focally immu-
noreactive for synaptophysin. Scale bars represent 100 μm.
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a highly malignant neoplasm, was originally interpreted as malig-
nant astroblastoma.
Histopathology of the recurrent tumor 8 months after gross total
resection showed a well-circumscribed tumor with morphology
similar to the prior specimen: small round blue cells with
hyperchromatic nuclei and high nuclear-to-cytoplasmic ratio.
Cells were arranged in sheets palisading around vessels forming
pseudorosettes. Mitoses and small cell necrosis were prominent.
There was focal parenchymal sclerosis within the tumor and some
vessels still displayed hyalinized walls. Immunohistochemical
studies showed focal immunoreactivity for GFAP and synapto-
physin in tumor cells (Figure 2). The tumor still had preservation
of INI-1, and the proliferation index was similar to the original
specimen. In view of the tumor’s aggressive behavior and rapid
recurrence after gross total resection and chemotherapy, the
pathology specimens were rereviewed, and the histological fea-
tures were considered to be more consistent with ETANTR than
malignant astroblastoma. In addition, molecular studies in the
recurrent tumor demonstrated focal amplification of chromosome
19q13.42 (Figure 3). A combination of clinicopathological and
molecular features in addition to the presence of this focal ampli-
fication confirmed the diagnosis of ETANTR.
Analysis of stem cell markers
Stem cell markers CD133, CD15 and nestin were analyzed at the
time of initial resection and at recurrence following chemotherapy.
Analysis by Western blot demonstrated a marked increase in
CD133 expression in the recurrent tumor in both the core and
periventricular regions compared with tumor at the time of initial
resection (Figure 4). RT-PCR quantification of CD133 transcript
levels showed a greater than 40- and 60-fold increase in CD133 in
the core and periventricular region of the recurrent tumor, respec-
tively, compared with the initial tumor (P < 0.05; Figure 4). There
was no difference in CD133 expression between the core and
Figure 3. Bar graph comparison of focal amplification of microRNA
(miR)-512 in the index case [embryonal tumor with abundant neuropil
and true rosettes (ETANTR) ], an embryonal tumor [atypical teratoid/
rhabdoid tumor (AT/RT)] and three normal brains. The genomic copy
number of miR-512 is compared with that of KIRL3DL3 within each
sample by reverse transcription-polymerase chain reaction (RT-PCR).
Both loci are located on chromosome 19q13.42; there is focal amplifi-
cation of distant regions within band 13, and sub-band 42 is observed
frequently in ependymoblastoma and ETANTR. miR-512 amplification is
significantly increased in ETANTR, confirming the diagnosis of ETANTR.
Figure 4. Stem cell marker expression pre- and post-chemotherapy.
A–E. CD133 expression. A–C. Immunofluorescence studies demon-
strate CD133 increases (P < 0.05) after chemotherapy, predominantly
in the tumor core area. D. Relative reverse transcription-polymerase
chain reaction (RT-PCR) demonstrates a 40- and 60-fold increase in
CD133 expression in core and periventricular regions, respectively,
after therapy (P < 0.05). E. Western blot analysis reveals increased
CD133 in both the core and periventricular regions of the recurrent
tumor compared with tumor at time of initial resection. F–J. CD15
expression. There is robust expression of CD15 on initial presentation,
dropping significantly after therapy, as seen on immunofluorescence
studies (P < 0.001) (F–H), RT-PCR (I) and total cell count (J). All
images at 40× magnification; scale bar represents 100 μm. DAPI, 4’,6-
diaminodino-2-phenylindole; GAPDH, glyceraldehyde 3-phosphate
dehydrogenase; mRNA, messenger RNA; PV, periventricular region.
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rim of the recurrent tumor. Fluorescently labeled tissue sections
confirmed increased density and distribution of CD133 immu-
noreactivity in the core and periventricular regions of the recurrent
tumor compared with the initial tumor, with 50–55 CD133+ cells
per high-powered field (HPF) compared with 20 cells per HPF in
the initial tumor (although this number did not reach statistical
significance given the sample size; P = 0.1; Figure 4). CD133
immunostaining showed a typical cell membrane distribution in
the small round cells of this tumor.
CD15 expression decreased precipitously in both the core and
periventricular region of the recurrent tumor compared with the
initial tumor (Figure 4). In the initial tumor, 87% of cells were
CD15+, but fewer than 1% of cells in the core and periventricular
region of the recurrent tumor were CD15+ (P < 0.001). Quantifi-
cation of CD15 transcript levels followed a similar pattern
(Figure 4). CD15 transcript levels were decreased 14- and 20-fold
in the core and periventricular regions of the recurrent tumor,
respectively, compared with the initial tumor.
Nestin expression was uniform and ubiquitous in sections of the
primary and recurrent tumor when examined by immunofluores-
cence. Cytoplasmic expression of nestin was observed in nearly all
cells of the tumor specimens. Blood vessels did not show nestin
immunoreactivity. There were no differences in nestin expression
seen by Western blot or RT-PCR analysis between pre- and post-
chemotherapy ETANTR specimens.
In summary, the recurrent tumor shows a significant increase in
CD133+ cells by Western blot and RT-PCR analysis. In contrast,
there was a significant decline in the subpopulation of CD15+ cells
post-chemotherapy.
DISCUSSION
ETANTR is a recently described embryonal neoplasm of the CNS.
It is histologically distinct and associated with a poor prognosis (8,
11, 19, 29). In this report, we describe TSC marker alterations in
ETANTR before and after chemotherapy.
According to the current WHO classification of CNS tumors
(24), ETANTR is an embryonal tumor that falls into the subgroup
of CNS PNET-NOS, which are composed of poorly differentiated
neuroepithelial cells. CNS PNETs that lack neural tube formation
(medulloepithelioma), true ependymoblastic rosettes (ependy-
moblastoma) or neuronal differentiation, with or without ganglion
cells (neuroblastoma or ganglioneuroblastoma), are classified
as CNS PNET-NOS. ETANTR has been described as a well-
circumscribed embryonal tumor of infancy with mixed features of
ependymoblastoma (multilayered ependymoblastic rosettes and
pseudorosettes) and neuroblastoma (neuroblastic rosettes) in the
presence of neuropil-like islands.
We present the case of a young child with a very aggressive
tumor that rapidly recurred after gross total resection, chemo-
therapy and radiation. Histology sections of the first resected
specimen showed a highly malignant neoplasm with prominent
necrosis and small round blue cells frequently arranged around
sclerotic blood vessels. Grossly the tumor appeared well circum-
scribed. The prominent vascular sclerosis and well-circumscribed
appearance of the tumor led to a diagnosis of malignant astro-
blastoma. Astroblastomas are considered to be circumscribed
vasocentric glial neoplasms of children, adolescents and young
adults. Histologically, astroblastomas are described as unipolar
cytoplasmic processes that anchor the tumor cell to the stroma of
a blood vessel, giving the appearance of pseudorosette or papillary
formation. Vascular and tissue sclerosis or hyalinization is often
seen. The tumor is thought to originate from the tanycyte, a cell
with intermediate features between astrocyte and ependymal cells.
Astroblastomas are rare tumors that have been divided into well-
differentiated and anaplastic (malignant) subtypes. The latter is
even rarer and has prominent mitotic activity, cytologic atypia and
architectural disorganization. It is thought that gross total resec-
tion, even in high-grade lesions, usually results in a favorable
outcome (3). The fact that the tumor recurred in such a short period
of time after gross total resection and aggressive therapy prompted
a review of the original pathology specimens.
As described earlier, this is a poorly differentiated tumor, with
only focal GFAP and synaptophysin expression seen in the speci-
men from the second resection. Both of these findings were seen in
a minority of the tumor cells, but are not uncommon in undiffer-
entiated tumors including malignant astroblastomas (4). The
presence of architectural features such as ependymoblastic and
neuronal rosettes with focal neuropil islands suggested that the
tumor was more consistent with the diagnosis of ETANTR. The
presence of a unique chromosome 19q13.42 amplification in this
case added clarity to the diagnosis.
A diverse set of molecular and genetic alterations in PNETs,
along with unique histological characteristics, validates the
subclassification of embryonal tumors into five distinct entities.
Medulloblastomas are commonly known by their i(17)q abnor-
malities. Similarly, AT/RT is characterized by mutations or loss of
the INI1 locus at 22q11.2. These changes are almost never found in
supratentorial PNET and therefore are considered to be a different
entity. Within PNETs, neuroblastomas show 13q telomeric dele-
tion, 14q deletion and homozygous deletion of 9p21.3 spanning
the CDKN2A and CDKN2B loci (20, 32). In contrast, chromosome
2 gain is frequently observed in ependymoblastoma and ETANTR
(6). More recently, a highly specific cluster of focal amplifica-
tions at chromosome region 19q13.42 were found in both
ependymoblastoma and ETANTR (15, 35). Focal amplification of
19q13.42 has previously been demonstrated in 11/45 PNETs that
were not further subclassified (21). miR-512 is one of 50 miRs
within chromosome 19q13.42. miR-512 was chosen for this
experiment because it has been shown to be one of seven focally
amplified miRs within this cluster and has a potentially oncogenic
role (21). This aberration is unique to ETANTR as it has not been
detected in any other pediatric brain tumors studied including 150
medulloblastomas, 122 ependymomas, 12 supratentorial PNETs
and 12AT/RTs (15, 17, 29, 30). The functional consequence of this
chromosomal amplification in ETANTR is unknown; however,
miR posttranscriptional silencing is a potential mechanism. Iden-
tification of amplification in this region and downstream effectors
may not only serve as diagnostic markers, but also as important
therapeutic targets for the development of novel treatment strate-
gies for these rare pediatric tumors.
The brain tumor initiating cell (BTIC) or TSC theory has pro-
vided a new pattern for understanding tumor cell biology. It sug-
gests that tumorigenic potential is limited to a subpopulation of
cells with stem-like properties with the ability to proliferate, self-
renew and differentiate into different lineages. Subpopulations of
human brain tumor cells expressing the surface markers CD133,
CD15 or nestin have been thought to behave in a “stem-like
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fashion” and have therefore been cautiously identified as markers
for BTICs in select tumor types (12, 18, 28).
CD133 is a stem cell marker expressed on neural, hepatic and
hematopoietic progenitor cells (27). Enhanced CD133 expression
has been correlated with poor prognosis and decreased survival
in patients with medulloblastoma and neuroblastoma (12, 34).
A higher proportion of CD133+ cells in medulloblastoma,
neuroblastoma and ganglioneuroblastoma correlated with shorter
survival and unfavorable histology (12, 34). Gowda et al (12)
analyzed the prevalence and prognostic significance of TSC
markers CD133 and CD15 in 60 cases of medulloblastoma.
They found 70% of medulloblastomas are CD133+, with positivity
as high as 17% of cells (12). CD133+ cells have also been shown
to be resistant to chemotherapy and radiation treatment (25).
Radioresistant and chemoresistant tumors display an enriched
population of CD133+ cells compared with the initial tumor popu-
lation. Our analysis of this patient with ETANTR is congruent with
these observations. Western blot analysis and RT-PCR demon-
strated that CD133 protein and transcript level is increased in the
recurrent form of the tumor compared with the tumor at the time
of initial resection. Although we have no functional cellular data
for further investigation, our data suggest that the small number of
CD133+ cells in the initial tumor may have been spared by the
initial chemotherapy regimen given to this patient. The recurrent
tumor’s enriched population of CD133+ cells likely survived
initial treatment, further contributing to the formation of the
recurrent tumor.
CD15, also known as stage-specific embryonic antigen 1
(SSEA-1/LeX), is a potential surface marker for BTICs first intro-
duced by Son et al (33). A CD15+ subpopulation has been iden-
tified in medulloblastoma and glioblastoma (12, 33). Sixty-seven
percent of medulloblastomas are CD15+ (with positivity as high as
17.1% of the population) (12). CD15+ cells have been shown to be
highly tumorigenic in vivo, and these cells also have self-renewal
and multi-lineage differentiation potential (33). Our results
showed a decrease in CD15+ cells following chemotherapy in
ETANTR. The depleted population of CD15+ cells after chemo-
therapy in ETANTR may be caused by effective treatment against
this subpopulation of cells by the therapeutic protocol given or the
failure of CD15+ cells to adequately label TSCs in ETANTR.
The immature intermediate filament, nestin, is commonly
expressed in CNS progenitor and neural stem cells. It is considered
a marker of poor prognosis and is also considered to be a brain
TSC marker for tumors originating from neuroectoderm (5, 18).
In a study of 22 pediatric brain tumors including gliomas
and medulloblastomas, Hemmati et al (13) showed that the most
common characteristic between tumor-derived neurospheres and
normal neural stem cells was the expression of CD133 and nestin.
Our study found no difference in the expression of nestin before or
after chemoradiation.
The subventricular zone adjacent to the lateral wall of the lateral
ventricle in the human CNS contains adult neural stem cells (14).
Some have suggested that tumors with a relationship to neural
stem cell regions display a more aggressive phenotype (22). For
this reason, recurrent ETANTR tumor specimens were taken from
both within the tumor core as well as from the region closest to
the lateral ventricular wall. Our results showed no difference in
CD133, CD15 or nestin positivity from these regions within
the tumor.
The rarity of this tumor limits robust experimental analysis.
Thus far, fewer than 30 cases have been described in the literature.
We present this observational data of TSC markers with caution,
noting the absence of validation in this paper or in the literature to
support proliferative, self-renewal or multi-lineage capacity of
CD133, CD15 or nestin-positive cells in ETANTR.
CONCLUSIONS
We observed an increase in protein level and transcript number of
the BTIC marker CD133 after chemotherapy and radiation in this
case of ETANTR. We also found a decrease in CD15 positivity.
While suggestive, this observational data must be further validated
with functional studies to prove whether or not this subpopulation
offers chemotherapy and radiation resistance in ETANTR. It may
be necessary to develop multifaceted and targeted therapeutic
strategies including those that target TSCs.
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